Conference Proceedings

Secondary mutations in RAD51C and RAD51D are associated with acquired resistance to the PARP inhibitor rucaparib in patients with high-grade ovarian cancer

K Lin, AV Tinker, O Kondrashova, G Ho, M Wakefield, RL Coleman, DM O'Malley, A Floquet, J Sun, L Maloney, H Giordano, T Harding, M Raponi, IA McNeish, E Swisher, CL Scott

European Journal of Cancer | ELSEVIER SCI LTD | Published : 2016